157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy

MLA

M. Casarrubios, et al. “157MO Immune Gene Signatures for Predicting Pathological Response of NSCLC Patients Treated with Neoadjuvant Chemoimmunotherapy.” Annals of Oncology, vol. 33, Apr. 2022, p. S105. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........b686184f7fcebe16935cd4a11e10289e&authtype=sso&custid=ns315887.

APA

M. Casarrubios, A. Cruz-Bermudez, B. Sierra-Rodero, E. Nadal, M.A. Insa Molla, M.R. Garcia Campelo, C. Garcia Benito, M. Domine Gomez, M. Majem Tarruella, D. Rodriguez-Abreu, A. Martinez, J. De Castro Carpeno, M. Cobo Dols, G. Lopez Vivanco, N. Vinolas Segarra, I.C. Barneto Aranda, S. Viteri, B. Massuti Sureda, & M. Provencio Pulla. (2022). 157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy. Annals of Oncology, 33, S105.

Chicago

M. Casarrubios, A. Cruz-Bermudez, B. Sierra-Rodero, E. Nadal, M.A. Insa Molla, M.R. Garcia Campelo, C. Garcia Benito, et al. 2022. “157MO Immune Gene Signatures for Predicting Pathological Response of NSCLC Patients Treated with Neoadjuvant Chemoimmunotherapy.” Annals of Oncology 33 (April): S105. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........b686184f7fcebe16935cd4a11e10289e&authtype=sso&custid=ns315887.